AI assistant
ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2009
Feb 2, 2009
33882_dirs_2009-02-02_442fd824-9a36-4eee-8c6c-5fedd0c2aadd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2008-08-21
Reporting Person: JACOBS CINDY (EVP, CMO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2008-08-21 | stock option (right to buy) | $4.1051 | A | 27221 | Acquired | 2012-09-12 | Common Stock (27221) | Direct |
Footnotes
F1: Due to an administrative error, the original Form 4 overstated the exercise price by $0.0026.
F2: Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 18.
F3: 20,416 options are exercisable as of 8/21/2008, the remaining 6,805 will become exercisable on 9/12/2008.
F4: Received in exchange for a stock option to acquire 125,000 shares of OncoGenex Technologies Inc.("OncoGenex Technologies")common stock for CAD$0.95 per share in connection with an arrangement between OncoGenex Technologies and OncoGenex Pharmaceuticals, Inc.